PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial
- Conditions
- Hernia, Ventral
- Interventions
- Drug: Methyl-PrednisoloneDrug: Physiological saline
- Registration Number
- NCT02594241
- Lead Sponsor
- Kristian Kiim Jensen
- Brief Summary
Patients who undergo abdominal wall reconstruction for giant ventral hernia repair will be randomized to either methylprednisolone or saline preoperatively, to examine the effects of methylprednisolone on postoperative pain, nausea and recovery after giant ventral hernia repair.
- Detailed Description
Preoperative high-dose glucocorticoid has been shown to attenuate the postoperative inflammatory response leading to decreased morbidity and length of stay (LOS) after colorectal and aortic surgery, as well as decreased pain and subjective recovery after orthopedic surgery. Methylprednisolone (MP, "Solu-Medrol") is one such glucocorticoid, which has been shown to be safe for usage in surgery. Giant ventral hernia repair is associated with a high risk of postoperative morbidity and prolonged LOS compared with other hernia repair procedures requiring laparotomy. Further, the total costs of these procedures remain high. Systemic administration of high-dose preoperative MP in ventral hernia repair has only been described anecdotally in the literature, and never with the aim to improve the treatment of this patient group specifically. It is however unknown to what extent benefits weigh out downsides from usage of high-dose MP in giant ventral hernia repair, patients often at increased risk of postoperative wound infection. On this background we hypothesize that a preoperative high-dose MP results in improved recovery after giant ventral hernia repair compared with placebo.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
- Ventral incisional hernia with horizontal fascial defect > 10 cm described at either computed tomography scan or clinical assessment
- Planned elective open hernia repair
- Ability to speak and understand Danish
- Ability to give written and oral informed consent
- Daily use of systemic glucocorticoid
- New York Heart Association class 3-4 heart disease
- Chronic renal failure (eGFR < 60 ml/min per 1.73 m2)
- Insulin-dependent diabetes
- Excessive abuse of alcohol
- Known allergy to methylprednisolone or any substance in study medicine
- Planned pregnancy within three months postoperatively
- Pregnancy, evaluated by pregnancy test preoperatively
- Breastfeeding
- Actively treated ulcer disease up to one month preoperatively
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Methylprednisolone Methyl-Prednisolone Patients in this arm will be given an intravenous infusion of 125 mg Methylprednisolone (Solu-Medrol) immediately after induction of general anesthesia. Physiological saline Physiological saline Patients in this arm will be given an intravenous infusion of saline immediately after induction of general anesthesia.
- Primary Outcome Measures
Name Time Method Pain at rest First postoperative day at 8 am Self-reported pain at rest on af numerical rating scale (0-10)
- Secondary Outcome Measures
Name Time Method Pain at rest, after moving from supine to sitting position and when coughing 8 am and 8 pm pre- and postoperatively until postoperative day 5 and again on day 30 Self-reported pain at rest, after moving from supine to sitting position and when coughing on af numerical rating scale (0-10)
Fatigue 8 am and 8 pm pre- and postoperatively until postoperative day 5 and again on day 30 Self-reported fatigue on a numerical rating scale (0-10)
Nausea 8 am and 8 pm pre- and postoperatively until postoperative day 5 and again on day 30 Self-reported nausea on a numerical rating scale (0-10)
Vomiting From randomization until postoperative day 5 Number of vomiting episodes
Time to fulfillment of discharge criteria From randomization until postoperative day 5, assessed at 8 am and 8 pm Patient's assessment of discharge criteria
30-postoperative complications From randomization and until 30-days postoperatively Complications that require surgical or medical intervention
30-day readmission From randomization and until 30-days postoperatively Patient readmission
Rescue analgesia intake From randomization and until day 5 postoperatively Need for intake of rescue analgesia postoperatively
C-reactive protein From day of randomization until postoperative day 3 Serum C-reactive protein preoperatively and on postoperative day 1-3.
Trial Locations
- Locations (1)
Bispebjerg Hospital
🇩🇰Copenhagen NV, Copenhagen, Denmark